Angina (Angina Pectoris) – Pipeline Review, 2019

Discomfort due to coronary heart disease or severe chest pain is referred to as angina pectoris.  The condition arises when arteries in supplying blood to the heart are blocked or narrowed and are unable to provide sufficient blood leading to severe chest pain. Symptoms of angina pectoris include episodes of chest pain, chest discomfort, and others. The major causes and risk factors for angina comprise of diabetes, high cholesterol, sedentary lifestyle, cigarette smoking, high blood pressure, and others. It has been observed that angina occurs when there is an imbalance between the heart’s oxygen demand and supply.

Current treatment of angina pectoris includes vasodilators such as nitro-glycerine. Along with these, beta blockers and calcium channel blockers are prescribed to decrease heart workload. Treatment of angina also includes surgical procedures such as angioplasty which comprises of inserting a balloon catheter to widen arterial lumen.

Many pharmaceutical companies have focussed on studying and developing new methods for the treatment of angina pectoris. For instance, MK-0974, which is being studied by Merck Sharp & Dohme Corp, is currently in phase-1 clinical trials for the study to assess the safety, tolerability, and effects of MK-0974 (telcagepant) in patients with stable angina.

To know how our report can help streamline your business, Speak to Analyst

At present more than 50% of the pipeline candidates for angina pectoris are in phase 2 and phase 3 stage. Majority of the studies have been sponsored by pharmaceutical companies. 

Report Description 

The report on ‘Angina (Angina Pectoris) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Angina (Angina Pectoris). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Angina (Angina Pectoris). 

The report on ‘Angina (Angina Pectoris) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

 Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Angina (Angina Pectoris)
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Angina (Angina Pectoris)
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary